U.S. Healthtech Stock News

NYSE:JNJ
NYSE:JNJPharmaceuticals

Johnson And Johnson’s Darzalex Home Use Approval Reshapes Myeloma Care Narrative

Johnson & Johnson (NYSE:JNJ) has secured European approval for self or caregiver administration of Darzalex in multiple myeloma. The decision covers all ten approved indications for Darzalex and makes it the first oncology injectable in Europe to receive this type of authorization. The new label allows eligible patients to receive treatment at home instead of exclusively in hospital or clinic settings. For Johnson & Johnson, which has a large pharmaceutical segment focused on oncology and...
NasdaqGS:QCOM
NasdaqGS:QCOMSemiconductor

Dividend Hike, Buyback And Downgrade Might Change The Case For Investing In QUALCOMM (QCOM)

Earlier in March 2026, QUALCOMM held its annual shareholder meeting, increased its quarterly dividend to US$0.92 per share, authorized a US$20.00 billion buyback, and filed a US$3.13 billion common share shelf registration tied to an employee stock ownership plan, while shareholder proposals on special meetings and China risk reporting were not approved. These moves highlight QUALCOMM’s focus on capital returns and employee ownership at the same time some investors are pushing for greater...
NYSE:ABBV
NYSE:ABBVBiotechs

Assessing AbbVie (ABBV) Valuation After New Dermatology Data Underpins Immunology Growth Potential

AbbVie’s dermatology data and why it matters for the stock AbbVie (ABBV) just put a spotlight on its dermatology franchise at the 2026 American Academy of Dermatology meeting, sharing 24 abstracts across psoriasis, atopic dermatitis, vitiligo and alopecia areata, including late-stage and long-term safety data. See our latest analysis for AbbVie. Despite the strong dermatology update, recent partnerships, and governance debates, AbbVie’s share price has slipped in recent months. Its year to...
NYSE:AORT
NYSE:AORTMedical Equipment

Is It Too Late To Reassess Artivion (AORT) After Its Strong Multi Year Share Price Run?

For investors considering whether Artivion at around US$35 per share still offers value or whether the recent run has already priced in the story, this article breaks down what the current market price might be implying. The stock has pulled back over the last week and month, with declines of 1.2% and 8.3%, respectively, while still sitting on a 43.6% return over 1 year and 176.1% over 3 years. Recent coverage has focused on Artivion's position in the medical equipment space and investor...
NYSE:CL
NYSE:CLHousehold Products

Does Governance Pressure and Legal Scrutiny Shift the Bull Case for Colgate-Palmolive’s (CL) Brand Strategy?

In March 2026, Colgate-Palmolive disclosed past shareholder proposals seeking an independent board chair and removal of DEI criteria from board candidate selection, while federal lawsuits challenged its mouth rinse packaging over alleged safety messaging for young children. These governance and legal pressures arrive just as Colgate-Palmolive promotes its new Optic White Pro Series Toothpaste, highlighting how product innovation now sits alongside intensified scrutiny of its board structure,...
NYSE:IT
NYSE:ITIT

Gartner (IT) Valuation Check After Sharp 3 Month And 1 Year Share Price Pullback

Event context and why Gartner is on investors’ radar Gartner (IT) has come into focus after a sharp share price pullback, with the stock showing a 38.95% decline over the past 3 months and a 62.97% negative total return over the past year. See our latest analysis for Gartner. At the current share price of US$155.42, Gartner’s recent performance reflects fading momentum, with a 7 day share price return of a 4.41% decline and a 1 year total shareholder return of a 62.97% decline. If Gartner’s...
NYSE:BFAM
NYSE:BFAMConsumer Services

Is Bright Horizons Family Solutions (BFAM) Offering Value After A Difficult Year For The Shares?

If you are wondering whether Bright Horizons Family Solutions at US$77.99 is priced attractively or asking too much for its prospects, the valuation picture is not as straightforward as the share price alone might suggest. The stock has seen a 4.7% gain over the past 30 days, but that sits against a 21.5% decline year to date and a 38.6% decline over the past year, which can shift how the market views both risk and potential reward. Recent coverage has focused on the company within the...
NYSE:TYL
NYSE:TYLSoftware

A Look At Tyler Technologies (TYL) Valuation As Analyst Optimism Builds Before Earnings And Investor Day

Recent analyst reports around Tyler Technologies (TYL) ahead of its upcoming fiscal first quarter 2026 earnings and June 9 investor day have drawn fresh attention to the stock, particularly given management’s long term 2030 financial targets and focus on SaaS. See our latest analysis for Tyler Technologies. Despite upbeat commentary around SaaS bookings and long term 2030 targets, Tyler Technologies’ share price has retreated, with a 90 day share price return of a 27.09% decline and a 1 year...
NYSE:KEY
NYSE:KEYBanks

KeyCorp Grant To Maine CDFI Puts Community Impact And Valuation In Focus

KeyBank, part of KeyCorp (NYSE:KEY), has partnered with Coastal Enterprises, Inc. to expand support for Maine entrepreneurs. The KeyBank Foundation awarded a US$200,000 grant in 2025 to CEI, a Maine based Community Development Financial Institution. The funding is intended to grow free and low cost business advising, and increase access to capital for entrepreneurs, especially in underserved and rural communities. For investors watching NYSE:KEY, this move highlights how a regional bank can...
NYSE:AFL
NYSE:AFLInsurance

The Bull Case For Aflac (AFL) Could Change Following New Hybrid Long-Term Care Rider Launch

In March 2026, Aflac Incorporated expanded its Group Life Term to 120 product by adding a hybrid long-term care rider that offers flexible, portable benefits usable for home- or facility-based care, including informal caregiving, though availability still varies by state. This innovation reflects Aflac’s push to address the “Silver Tsunami” and rising long-term care costs by letting policyholders tap life coverage during their lifetimes rather than only after death. Next, we’ll examine how...
NYSE:XPRO
NYSE:XPROEnergy Services

A Look At Expro Group Holdings (XPRO) Valuation After New Geothermal Contract For Vulcan’s Lionheart Project

Expro Group Holdings (XPRO) has been tapped to provide well testing services for Vulcan Energy’s Lionheart Project in Europe’s largest geothermal and lithium cluster, putting fresh attention on how this contract fits into the stock’s recent return profile. See our latest analysis for Expro Group Holdings. The Lionheart contract comes at a time when Expro’s 90 day share price return of 32.37% and 1 year total shareholder return of 80.18% have already drawn attention, following a relatively...
NYSE:PVH
NYSE:PVHLuxury

Lower Special-Meeting Threshold Could Be A Game Changer For PVH’s Shareholder Influence (PVH)

On March 20, 2026, PVH Corp.’s Board of Directors amended the company’s by-laws to lower the ownership threshold for shareholders to request a special meeting from a majority of outstanding common shares to 25%, adding new conditions and conforming governance provisions. This shift meaningfully increases the potential influence of significant shareholders over PVH’s corporate agenda, signaling a greater openness to investor input on key governance and strategic matters. Next, we’ll examine...
NYSE:KRG
NYSE:KRGRetail REITs

Assessing Kite Realty Group Trust (KRG) Valuation After Recent Share Price Pullback

Event context and recent share performance Kite Realty Group Trust (KRG) has drawn investor attention after recent share price moves, with the stock down about 7% over the past month but roughly flat over the past 3 months. See our latest analysis for Kite Realty Group Trust. For context, the recent 7.3% 1 month share price decline comes after a relatively steady 1 year total shareholder return of 14.2% and 3 year total shareholder return of 33.4%. This suggests momentum has cooled in the...
NYSE:WBS
NYSE:WBSBanks

A Look At Webster Financial (WBS) Valuation After Mixed Recent Shareholder Returns

What Webster Financial’s recent returns suggest for investors Webster Financial (WBS) has drawn attention after a recent one-month return decline of about 6% contrasted with a gain of roughly 6% over the past 3 months, prompting closer scrutiny of its fundamentals. For investors tracking banks, this mix of short term weakness and recent quarter strength raises questions about how the current share price of US$68.07 lines up with Webster Financial’s earnings profile, balance across business...
NasdaqGS:GTX
NasdaqGS:GTXAuto Components

Will Rising Free Cash Flow Efficiency and Higher ROIC Change Garrett Motion's (GTX) Investment Narrative?

In recent years, Garrett Motion has reported stronger quarterly results alongside rising free cash flow margins and higher returns on invested capital, indicating more efficient operations. These improvements in cash generation and capital productivity suggest the company has been reshaping its business model to rely less on heavy investment needs. We’ll now examine how this improved free cash flow efficiency interacts with Garrett Motion’s existing investment narrative and future business...
NasdaqGS:COIN
NasdaqGS:COINCapital Markets

Is It Time To Reassess Coinbase Global (COIN) After The Recent Share Price Slump?

For investors considering whether Coinbase Global at around US$161 per share is a bargain, fairly priced, or expensive, this article explains what the current stock price might indicate about value. The stock has experienced volatility recently, with a 19.7% decline over the last 7 days and a 31.9% decline year to date. Over a 3 year period the return stands at 153.3%, while the 1 year return reflects a 6.4% decline. Recent price movements have occurred against a backdrop of ongoing interest...
NasdaqGS:ADBE
NasdaqGS:ADBESoftware

Adobe CEO Retirement Puts AI Plans And ARR Transparency In Focus

Adobe CEO Shantanu Narayen has announced plans to retire, triggering a CEO search at NasdaqGS:ADBE. The leadership change comes as Adobe faces intensifying AI driven competition and regulatory attention. The transition coincides with adjustments to how Adobe reports certain ARR metrics, affecting visibility into some recurring revenue trends. Adobe sits at the center of digital media and marketing software, with Creative Cloud, Document Cloud, and Experience Cloud anchoring its business...
NasdaqGS:VRNS
NasdaqGS:VRNSSoftware

A Look At Varonis Systems (VRNS) Valuation After Recent Share Price Weakness

Varonis Systems (VRNS) has drawn investor attention after recent trading left the stock with a negative return over the past year and over the past 3 months, prompting closer scrutiny of its fundamentals. See our latest analysis for Varonis Systems. At a share price of $21.21, Varonis Systems has seen a 36.38% 3 month share price decline and a 49.06% 1 year total shareholder return decline, suggesting fading momentum as investors reassess growth expectations and risk. If recent weakness in...
NasdaqGS:AMZN
NasdaqGS:AMZNMultiline Retail

Amazon Weighs AI Chip Turnover And Data Ruling Against Valuation Upside

Amazon.com (NasdaqGS:AMZN) has seen another senior departure from its Annapurna Labs chip unit, which develops the Trainium AI chips used in AWS infrastructure. The exit follows earlier leadership changes in the group, as Amazon pursues a reported US$200b in AI related capital spending. Separately, Amazon secured a legal win against Perplexity that restricts AI agents from scraping its marketplace data. The ruling is intended to protect Amazon's retail and advertising ecosystem from third...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

AI-Enabled ATTR-CM Care Pathway Initiative Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals recently outlined new efforts to improve earlier recognition and coordinated care for cardiomyopathy in wild-type and hereditary transthyretin-mediated amyloidosis, partnering with Viz.ai to integrate an FDA-cleared echocardiography AI algorithm into real-world clinical workflows through the AWARE study at five US health systems. In parallel, Alnylam is backing a three-year American Heart Association program that will convene a 10-center national learning...
NYSE:EQH
NYSE:EQHDiversified Financial

Is Equitable Holdings (EQH) Pricing Reflect A Recovery Opportunity After Recent Share Price Slump

Wondering whether Equitable Holdings at around US$35.34 is a bargain or a value trap? This article focuses squarely on what the current price might imply. The stock has had a tough period recently, with a 7.2% decline over the last week, 12.1% over the last month and a 26.3% drop year to date, even though the 3 year and 5 year returns sit at 51.9% and 20.0% respectively. Recent coverage has highlighted Equitable Holdings as a diversified financial name that has seen sharp price swings,...
NYSE:APO
NYSE:APODiversified Financial

Apollo Expands Beyond New York As Stock Trades Below Estimated Value

Apollo Global Management (NYSE:APO) plans to establish a second US headquarters outside New York. The firm is evaluating locations in the American South, including Austin, Nashville, and South Florida. The new hub is intended to support future hiring and organizational growth across the business. Apollo Global Management, trading at $108.42, is taking a significant step by planning a second US headquarters alongside its New York base. The company has seen mixed share performance, with a...
NYSE:DGX
NYSE:DGXHealthcare

A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Swings

Quest Diagnostics (DGX) continues to draw interest after recent share price swings, with the stock down around 8% over the past month but showing a positive total return over the past 3 months and year. See our latest analysis for Quest Diagnostics. The recent 30 day share price return of negative 7.7% contrasts with a 12.5% year to date share price gain and a 1 year total shareholder return of 17.7%. This suggests momentum has cooled after a stronger run, but longer term holders have still...
NYSE:ORA
NYSE:ORARenewable Energy

How Investors May Respond To Ormat Technologies (ORA) 2031 Convertible Notes And Dilution Trade-Off

Earlier this month, Ormat Technologies, Inc. completed two Rule 144A convertible note offerings totaling US$750,000,000, including zero-coupon and 1.5% senior unsecured notes due March 15, 2031. This mix of zero-coupon and low-coupon convertible debt materially expands Ormat’s financial flexibility while potentially introducing future equity dilution if the notes are converted. We’ll now explore how this sizeable 2031 convertible issuance could influence Ormat’s investment narrative around...